Stock Research
|
(PFE) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
June 18, 2013
(Jutia Group,
3/6/13)
Generic drug companies are standing on the cusp of a once-in-a-lifetime opportunity.
In the next five years, a total of $290 billion in prescription drug sales are expected...(read more)
(Value Investing,
10/22/12)
On Monday, Pfizer Inc. (NYSE:PFE) announced plans to purchase an attention-deficit/hyperactivity (ADHD) disorder drug developer, NextWave Pharmaceuticals. The deal could carry a $700...(read more)
(Stock Blog Hub,
9/18/12)
Pfizer Inc. (PFE) recently announced European Commission approval of its renal cell cancer drug, Inlyta (axitinib). Inlyta gained approval from the EC for use in...(read more)
Pfizer (PFE) Company Overview
Pfizer Inc. (NYSE:PFE) is the largest pharmaceutical company in the world. It owns the best selling medicine in the world, cholesterol-lowering drug Lipitor and has 14 other blockbuster drugs (annual sales >$1B).[1] In FY 2010, Pfizer generated revenues of $67.8 billion and net income of $8.26B.[2] As the largest player in the pharmaceutical market, Pfizer has greater power in marketing and forming alliances.[3] The company also consistently posts the highest dividends in the industry.[3] However, Pfizer faces challenges common to all players in the pharmaceutical industry, including issues surrounding patent expiration and FDA regulation. (Read more at Wikinvest ) What's in this PFE analysis on Wikinvest...
|
©2013 MoneyShow.com, LLC. All Rights Reserved. For a complete trademark notice, please see the Terms of Service